AT1 受体的中药活性成分筛选模型及其作用机理研究

doi:10.6023/A1109071

化学学报 ›› 2012, Vol. 70 ›› Issue (06): 796-802.DOI: 10.6023/A1109071 上一篇下一篇

研究论文

AT₁ 受体的中药活性成分筛选模型及其作用机理研究

吴琼^a, 康宏^b, 王欢欢^a, 高军^b,c, 朱瑞新^a,b, 康廷国^a

a 辽宁中医药大学药学院大连 116600;
b 同济大学生命科学与技术学院上海 200092;
c 上海海事大学信息工程学院上海 201306

投稿日期:2011-09-07 修回日期:2011-11-28 发布日期:2011-12-19
通讯作者: 朱瑞新
基金资助:
国家自然科学基金(No. 30976611)、高等学校博士学科点专项科研基金(No. 2010-0072120050)资助项目.

AT1R-based Virtual Screening Model for Bioactive Components from Traditional Chinese Medicines and Its Mechanism Study

Wu Qiong^a, Kang Hong^b, Wang Huanhuan^a, Gao Jun^b,c, Zhu Ruixin^a,b, Kang Tingguo^a

a School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China;
b School of Life Sciences and Technology, Tongji University, Shanghai 200092, China;
c School of Information Engineering, Shanghai Maritime University, Shanghai 201306, China

Received:2011-09-07 Revised:2011-11-28 Published:2011-12-19
Supported by:
Project supported by the National Natural Science Foundation of China (No. 30976611), the Specialized Research Fund for the Doctoral Program of Higher Education of China (No. 2010-0072120050).

文章分享

摘要/Abstract

传统中药对治疗心血管类疾病疗效显著, 例如钩藤、黄芪、益母草等在临床应用广泛. 现代药理研究表明钩藤碱可以降压; 黄芪中毛蕊异黄酮能舒张血管平滑肌、保护心脑血管; 益母草碱可扩张微血管, 改善血液流变异常, 但它们分子层面作用机制尚不明确. 首先以牛视紫红质蛋白为模板, 模建出心血管疾病主要靶点AT₁ 受体的三维结构. 然后将AT₁ 受体拮抗剂和中药活性成分与受体模型结合的作用方式进行了对比研究, 据此提出了中药活性成分治疗心血管疾病的作用机理, 并建立了AT₁受体的中药活性成分筛选模型. 结果表明: 黄芪毛蕊异黄酮等中药活性成分能与AT₁受体活性口袋中的残基发生氢键作用, 结合方式与AT₁ 受体拮抗剂相似. 每一种AT₁ 受体拮抗剂均与 His183, Lys199,His256, Gln257, Ser105, Ser109, Tyr113, Asn200 中多个发生氢键作用; 黄芪毛蕊异黄酮与Try113, Lys199, Gln257,Ser105 发生氢键作用. 本研究从分子层面上阐释了一些中药活性小分子的治病机理, 为进一步挖掘中药资源, 研究AT₁ 受体相关的心脑血管类药物, 合理设计和筛选AT₁ 受体的拮抗剂提供重要依据.

关键词: AT₁ 受体, 中药活性成分, 同源模建, 分子对接, 分子机理

The traditional Chinese medicine (TCM) has a significant effect on the treatment of cardiovascular diseases and some has been widely used in clinical therapy, such as Uncaria, Astragalus and Motherwort. The previous research found that Rhy could lower blood pressure; Calycosin in Astragalus could relax vascular smooth muscle, protect cardiovascular and cerebrovascular; and Leonurine could increase telangiectasia, improve abnormity of hemorheology; however, the mechanism of these was not clear. Here, the structure of receptor AT₁, which was the main target of cardiovascular diseases, has been modeled based on the crystal structure of bovine rhodopsin; meanwhile, the interaction of receptor AT₁ antagonists to receptor AT₁ was compared with that of the active compounds in TCMs. The results indicated that Calycosin and Leonurine could bind the residues Try113, Lys199, Gln257, Ser105 by hydrogen bonds, and the mechanism was similar with receptor AT₁ antagonists which bound with the residues His183, Lys199, His256, Gln257,Ser105, Ser109, Tyr113, Asn200. In this study, the mechanism of some TCM active compounds was explained on molecular level, which provided a foundation for further screening and rational design of AT₁R antagonists from traditional Chinese medicine.

Key words: angiotensin Ⅱ type 1 receptor, active components in traditional Chinese medicine, homology model, molecular docking, molecular mechanism

引用此文

吴琼, 康宏, 王欢欢, 高军, 朱瑞新, 康廷国. AT₁ 受体的中药活性成分筛选模型及其作用机理研究[J]. 化学学报, 2012, 70(06): 796-802.

Wu Qiong, Kang Hong, Wang Huanhuan, Gao Jun, Zhu Ruixin, Kang Tingguo. AT1R-based Virtual Screening Model for Bioactive Components from Traditional Chinese Medicines and Its Mechanism Study[J]. Acta Chimica Sinica, 2012, 70(06): 796-802.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

参考文献

1 Du, X.-K.; Li, B. J. Liaoning Univ. Trad. Chin. Med. 2008,10(12), 18 (in Chinese). (杜杏坤, 黎波, 辽宁中医药大学学报, 2008, 10(12), 18.)

2 Lu, J.-J. J. Guangzhou Univ. Trad. Chin. Med. 2008, 25(2),180 (in Chinese). (卢建军, 广州中医药大学学报, 2008, 25(2), 180.)

3 He, Q.-Y. Ph.D. Dissertation, Beijing University of Traditional Chinese Medicine, Beijing, 2011 (in Chinese). (何庆勇, 博士论文, 北京中医药大学, 北京, 2011)

4 Li, H. M.S. Thesis, Beijing University of Traditional Chinese Medicine, Beijing, 2002 (in Chinese). (李辉, 硕士论文, 北京中医药大学, 北京, 2002)

5 Li, Y.; Wu, Q.; Lin, Q. Chin. J. Basic Med. Trad. Chin. Med. 2010, 16(7), 597 (in Chinese). (李岩, 武乾, 林谦, 中国中医基础医学杂志, 2010, 16(7),597.)

6 Wang, C.; Wang, C.-H.; Li, F.; Zhang, C.-X. J. Emerg. Tradit. Chin. Med. 2009, 18(6), 962 (in Chinese). (王超, 王长海, 李锋, 张春许, 中国中医急症, 2009,18(6), 962.)

7 Regitz-Zagrosek, V.; Auch-Schwelk, W.; Neuss, M.; Fleck, E. Eur. Heart J. 1994, 15, Suppl D: 92～97.

8 Monnot, C.; Bihoreau, C.; Conchon, S.; Curnow, K. M.; Corvol, P.; Clauser, E. J. Biol. Chem. 1996, 271(3), 1507.

9 http://www.expasy.org/sprot/

10 http://www.ebi.ac.uk/Tools/msa/

11 Molecular Operation Environment, version 2008.10, Chemical Computing Group Inc., Montreal, Quebec, Canada,2008.

12 http://www.uniprot.org/

13 Miura, S.; Saku, K.; Karnik, S. S. Hypertens. Res. 2003,26(12), 937.

14 Li, C.-F.; Gao, D.-S. Medical Recapitulate 2009, 15(13),1932 (in Chinese). (李传方, 高东升, 医学综述, 2009, 15(13), 1932.)

15 Lorell, B. H. Am. J. Cardiol. 1999, 83(12A), 48H.

16 Li, Y.-Q.; Gao, G.-D. J. Xi'an Med. Univ. 1997, 18(2), 275 (in Chinese). (李永勤, 高广道, 西安医科大学学报, 1997, 18(2), 275.)

17 Dai, M.-S.; Zhu, Q.-Y.; Su, D.-F. J. Pharmaceutical Practice1995, 13(3), 141 (in Chinese). (戴生明, 朱铨英, 苏定冯, 药学实践杂志, 1995, 13(3),141.)

18 Allen, A. M.; Zhuo, J.; Mendelsohn, F. A. Am. J. Hypertens.2000, 13(1 Pt 2), 31S.

19 Mukoyama, M.; Nakajima, M.; Horiuchi, M.; Sasamura, H.; Pratt, R. E.; Dzau, V. J. J. Biol. Chem. 1993, 268(33),24539.

20 Sasamura, H.; Hein, L.; Krieger, J. E.; Pratt, R. E.; Kobilka, B. K.; Dzau, V. J. Biochem. Biophys. Res. Commun. 1992,185(1), 253.

21 Liu, H.-B.; Cui, W.; Xu, J.; Peng, Y.; Zhou, J.-J.; Xiao, P.-G. Acta Phys.-Chim. Sin. 2010, 26(9), 2549 (in Chinese). (刘海波, 崔巍, 徐峻, 彭勇, 周家驹, 肖培根, 物理化学学报, 2010, 26(9), 2549.)

22 Fu, C.-M.; Zhang, J.-M.; Xu, L.-J.; You, Y.; Fu, X.-H. Asia-Pacific Traditional Medicine 2010, 6(4), 4 (in Chinese). (傅超美, 章津铭, 许丽佳, 游宇, 付薛衡, 亚太传统医药, 2010, 6(4), 4.)

23 Guharoy, M.; Chakrabarti, P. BMC Bioinformatics 2010, 11,286.

24 Wang, L.; Berne, B. J.; Friesner, R. A. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(4), 1326.

25 Zoumpoulakis, P.; Daliani, I.; Zervou, M.; Kyrikou, I.; Siapi, E.; Lamprinidis, G.; Mikros, E.; Mavromoustakos, T. Chem. Phys. Lipids 2003, 125(1), 13.

[1]	李瑶, 陈丙年, 罗丹, 雷珊, 王力. 多酸型α-葡萄糖苷酶抑制剂的抗氧化性能研究[J]. 化学学报, 2023, 81(10): 1318-1326.
[2]	陈祥松, 帅蝶, 姜泽东, 杨晗, 罗丹, 倪辉, 王力, 陈丙年. H₆[P₂Mo₁₈O₆₂]的钒取代多金属氧酸盐对小鼠黑色素瘤细胞B16黑色素生成的调控及其机制研究[J]. 化学学报, 2022, 80(2): 116-125.
[3]	徐婕, 魏雨晨, 伍智蔚, 易忠胜. 基于酸度诱导的HSA与BDE154的光谱和计算模拟研究[J]. 化学学报, 2018, 76(5): 408-414.
[4]	李博, 周锐, 何谷, 郭丽, 黄维. 螺环吲哚类MDM2抑制剂的分子对接、定量构效关系和分子动力学模拟[J]. 化学学报, 2013, 71(10): 1396-1403.
[5]	王媛, 蒋勇军, 张美青, 沈银. α-咔啉类GSK-3β抑制剂的合成、活性评价和分子对接研究[J]. 化学学报, 2012, 70(18): 1974-1978.
[6]	林军, 李祖光, 邹建卫, 陆绍永. 基于HPPD 靶标酶的分子对接研究[J]. 化学学报, 2012, 70(11): 1309-1314.
[7]	安康, 柴晓杰, 薛飞, 王媛, 张婷. VEGFR-2 与抑制剂Sunitinib 的分子对接及分子动力学研究[J]. 化学学报, 2012, 70(10): 1232-1236.
[8]	詹冬玲, 王嵩, 韩葳葳, 刘景圣. 人参β-香树素合成酶同源模建及高通量虚拟筛选抑制剂的研究[J]. 化学学报, 2012, 70(03): 217-222.
[9]	唐典勇, 刘嵬, 胡建平, 孙国峰, 张元勤, 常珊. 戊烷与颗粒型甲烷单加氧酶的相互作用研究[J]. 化学学报, 2011, 69(24): 2939-2946.
[10]	郑蓉, 吕暾. 毒素DON单链抗体的同源建模及与DON结合的分子模拟研究[J]. 化学学报, 2011, 69(23): 2882-2888.
[11]	吕婧, 蒋勇军, 俞庆森, 邹建卫. 洋刀豆脲酶与抑制剂相互作用的分子对接和分子动力学研究[J]. 化学学报, 2011, 69(20): 2427-2433.
[12]	郑杰, 赵斌, 闫鸿鹏, 张焜, 张大鹏, 赵肃清. 雪卡毒素毒性机理的分子对接及分子动力学研究[J]. 化学学报, 2011, 69(17): 2026-2030.
[13]	杨锐, 韩葳葳, 王嵩. 极光激酶A抗癌抑制剂的高通量筛选及对接研究[J]. 化学学报, 2011, 69(12): 1399-1402.
[14]	涂国刚, 李少华. 大麻素受体CB1三维结构的同源模建及其对接研究[J]. 化学学报, 2011, 69(08): 1007-1010.
[15]	杨志伟, 祖元刚, 吴晓敏, 刘成卜, 杨刚. 神经氨酸酶与3-(3-戊氧基)安息香酸作用机制的理论研究[J]. 化学学报, 2010, 68(14): 1370-1378.

AT₁ 受体的中药活性成分筛选模型及其作用机理研究

AT1R-based Virtual Screening Model for Bioactive Components from Traditional Chinese Medicines and Its Mechanism Study

PDF

可视化

摘要/Abstract

引用此文

分享此文

参考文献

相关文章 15

编辑推荐

相关统计

本文评价